Bicara Therapeutics (NASDAQ:BCAX) Trading 6.5% Higher – Still a Buy?

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s share price was up 6.5% on Friday . The stock traded as high as $15.95 and last traded at $16.4240. Approximately 24,865 shares changed hands during trading, a decline of 94% from the average daily volume of 396,446 shares. The stock had previously closed at $15.42.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Citigroup started coverage on Bicara Therapeutics in a report on Thursday, January 29th. They set an “outperform” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.33.

Bicara Therapeutics Price Performance

The firm has a fifty day simple moving average of $16.51 and a two-hundred day simple moving average of $15.32. The firm has a market capitalization of $847.99 million, a P/E ratio of -6.91 and a beta of -0.79.

Insider Transactions at Bicara Therapeutics

In related news, insider David Raben sold 5,500 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $18.45, for a total value of $101,475.00. Following the sale, the insider directly owned 35,497 shares in the company, valued at approximately $654,919.65. The trade was a 13.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Claire Mazumdar sold 41,163 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $18.86, for a total transaction of $776,334.18. Following the sale, the chief executive officer directly owned 309,892 shares in the company, valued at approximately $5,844,563.12. This trade represents a 11.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 82,817 shares of company stock worth $1,547,537. Insiders own 15.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP lifted its position in shares of Bicara Therapeutics by 2.0% during the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after acquiring an additional 100,000 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after purchasing an additional 2,771,868 shares during the period. Janus Henderson Group PLC purchased a new stake in Bicara Therapeutics during the 4th quarter worth about $44,484,000. Vanguard Group Inc. boosted its stake in Bicara Therapeutics by 9.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after purchasing an additional 195,667 shares during the period. Finally, State Street Corp grew its holdings in Bicara Therapeutics by 179.5% during the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after buying an additional 1,059,260 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.